nodes	percent_of_prediction	percent_of_DWPC	metapath
Tapentadol—UGT1A9—Irinotecan—hematologic cancer	0.0562	0.1	CbGbCtD
Tapentadol—UGT2B7—Epirubicin—hematologic cancer	0.0546	0.0977	CbGbCtD
Tapentadol—CYP2C9—Bexarotene—hematologic cancer	0.0335	0.0598	CbGbCtD
Tapentadol—CYP2D6—Lomustine—hematologic cancer	0.0284	0.0509	CbGbCtD
Tapentadol—CYP2C9—Idarubicin—hematologic cancer	0.0277	0.0496	CbGbCtD
Tapentadol—CYP2D6—Idarubicin—hematologic cancer	0.0254	0.0453	CbGbCtD
Tapentadol—CYP2C19—Bortezomib—hematologic cancer	0.0247	0.0441	CbGbCtD
Tapentadol—CYP2D6—Hydroxyurea—hematologic cancer	0.0216	0.0385	CbGbCtD
Tapentadol—CYP2C19—Thalidomide—hematologic cancer	0.0215	0.0384	CbGbCtD
Tapentadol—CYP2C9—Bortezomib—hematologic cancer	0.0205	0.0367	CbGbCtD
Tapentadol—CYP2C19—Teniposide—hematologic cancer	0.0205	0.0367	CbGbCtD
Tapentadol—CYP2C19—Ifosfamide—hematologic cancer	0.0189	0.0338	CbGbCtD
Tapentadol—CYP2D6—Bortezomib—hematologic cancer	0.0188	0.0335	CbGbCtD
Tapentadol—CYP2C19—Imatinib—hematologic cancer	0.0181	0.0323	CbGbCtD
Tapentadol—CYP2C9—Thalidomide—hematologic cancer	0.0179	0.0319	CbGbCtD
Tapentadol—CYP2C9—Teniposide—hematologic cancer	0.017	0.0305	CbGbCtD
Tapentadol—CYP2C9—Ifosfamide—hematologic cancer	0.0157	0.0281	CbGbCtD
Tapentadol—CYP2C9—Imatinib—hematologic cancer	0.015	0.0269	CbGbCtD
Tapentadol—CYP2D6—Imatinib—hematologic cancer	0.0137	0.0246	CbGbCtD
Tapentadol—CYP2C9—Nilotinib—hematologic cancer	0.0137	0.0244	CbGbCtD
Tapentadol—CYP2D6—Nilotinib—hematologic cancer	0.0125	0.0223	CbGbCtD
Tapentadol—CYP2D6—Vinorelbine—hematologic cancer	0.0124	0.0221	CbGbCtD
Tapentadol—CYP2C19—Prednisone—hematologic cancer	0.0119	0.0213	CbGbCtD
Tapentadol—CYP2C9—Cisplatin—hematologic cancer	0.00765	0.0137	CbGbCtD
Tapentadol—CYP2D6—Vinblastine—hematologic cancer	0.00763	0.0136	CbGbCtD
Tapentadol—CYP2C19—Dexamethasone—hematologic cancer	0.00743	0.0133	CbGbCtD
Tapentadol—CYP2C9—Dexamethasone—hematologic cancer	0.00618	0.0111	CbGbCtD
Tapentadol—CYP2D6—Dexamethasone—hematologic cancer	0.00565	0.0101	CbGbCtD
Tapentadol—CYP2D6—Doxorubicin—hematologic cancer	0.00469	0.00838	CbGbCtD
Tapentadol—HTR3A—hematopoietic system—hematologic cancer	0.00067	0.0914	CbGeAlD
Tapentadol—OPRM1—hematopoietic system—hematologic cancer	0.000615	0.0838	CbGeAlD
Tapentadol—SLC6A4—hematopoietic system—hematologic cancer	0.000511	0.0697	CbGeAlD
Tapentadol—UGT2B7—testis—hematologic cancer	0.000504	0.0686	CbGeAlD
Tapentadol—HTR3A—blood—hematologic cancer	0.000444	0.0605	CbGeAlD
Tapentadol—CYP2C19—hematopoietic system—hematologic cancer	0.000424	0.0577	CbGeAlD
Tapentadol—OPRM1—blood—hematologic cancer	0.000407	0.0555	CbGeAlD
Tapentadol—HTR3A—lung—hematologic cancer	0.000389	0.0531	CbGeAlD
Tapentadol—SLC6A2—gonad—hematologic cancer	0.000342	0.0466	CbGeAlD
Tapentadol—SLC6A4—blood—hematologic cancer	0.000339	0.0462	CbGeAlD
Tapentadol—OPRM1—testis—hematologic cancer	0.000337	0.0459	CbGeAlD
Tapentadol—CYP2C9—hematopoietic system—hematologic cancer	0.000328	0.0448	CbGeAlD
Tapentadol—SLC6A4—lung—hematologic cancer	0.000297	0.0405	CbGeAlD
Tapentadol—CYP2C19—blood—hematologic cancer	0.000281	0.0382	CbGeAlD
Tapentadol—SLC6A2—lung—hematologic cancer	0.000261	0.0356	CbGeAlD
Tapentadol—SLC6A2—testis—hematologic cancer	0.000247	0.0336	CbGeAlD
Tapentadol—CYP2D6—hematopoietic system—hematologic cancer	0.000246	0.0336	CbGeAlD
Tapentadol—CYP2C9—blood—hematologic cancer	0.000218	0.0296	CbGeAlD
Tapentadol—SLC6A2—lymph node—hematologic cancer	0.000179	0.0244	CbGeAlD
Tapentadol—CYP2D6—blood—hematologic cancer	0.000163	0.0222	CbGeAlD
Tapentadol—CYP2D6—testis—hematologic cancer	0.000135	0.0184	CbGeAlD
Tapentadol—Vomiting—Gemcitabine—hematologic cancer	5.37e-05	0.000167	CcSEcCtD
Tapentadol—Insomnia—Dexamethasone—hematologic cancer	5.36e-05	0.000167	CcSEcCtD
Tapentadol—Insomnia—Betamethasone—hematologic cancer	5.36e-05	0.000167	CcSEcCtD
Tapentadol—Bradycardia—Doxorubicin—hematologic cancer	5.36e-05	0.000167	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	5.35e-05	0.000166	CcSEcCtD
Tapentadol—Paraesthesia—Dexamethasone—hematologic cancer	5.33e-05	0.000166	CcSEcCtD
Tapentadol—Paraesthesia—Betamethasone—hematologic cancer	5.33e-05	0.000166	CcSEcCtD
Tapentadol—Mental disorder—Methotrexate—hematologic cancer	5.32e-05	0.000166	CcSEcCtD
Tapentadol—Rash—Gemcitabine—hematologic cancer	5.32e-05	0.000166	CcSEcCtD
Tapentadol—Dermatitis—Gemcitabine—hematologic cancer	5.32e-05	0.000165	CcSEcCtD
Tapentadol—Eye disorder—Epirubicin—hematologic cancer	5.31e-05	0.000165	CcSEcCtD
Tapentadol—Hypersensitivity—Etoposide—hematologic cancer	5.31e-05	0.000165	CcSEcCtD
Tapentadol—Malnutrition—Methotrexate—hematologic cancer	5.29e-05	0.000165	CcSEcCtD
Tapentadol—Headache—Gemcitabine—hematologic cancer	5.29e-05	0.000164	CcSEcCtD
Tapentadol—Nausea—Vincristine—hematologic cancer	5.28e-05	0.000164	CcSEcCtD
Tapentadol—Cardiac disorder—Epirubicin—hematologic cancer	5.28e-05	0.000164	CcSEcCtD
Tapentadol—Hypersensitivity—Prednisolone—hematologic cancer	5.24e-05	0.000163	CcSEcCtD
Tapentadol—Hypoaesthesia—Doxorubicin—hematologic cancer	5.23e-05	0.000163	CcSEcCtD
Tapentadol—Dyspepsia—Dexamethasone—hematologic cancer	5.22e-05	0.000162	CcSEcCtD
Tapentadol—Dyspepsia—Betamethasone—hematologic cancer	5.22e-05	0.000162	CcSEcCtD
Tapentadol—Urinary tract disorder—Doxorubicin—hematologic cancer	5.2e-05	0.000162	CcSEcCtD
Tapentadol—Urticaria—Triamcinolone—hematologic cancer	5.19e-05	0.000162	CcSEcCtD
Tapentadol—Asthenia—Etoposide—hematologic cancer	5.17e-05	0.000161	CcSEcCtD
Tapentadol—Connective tissue disorder—Doxorubicin—hematologic cancer	5.17e-05	0.000161	CcSEcCtD
Tapentadol—Anaphylactic shock—Prednisone—hematologic cancer	5.16e-05	0.000161	CcSEcCtD
Tapentadol—Oedema—Prednisone—hematologic cancer	5.16e-05	0.000161	CcSEcCtD
Tapentadol—Angiopathy—Epirubicin—hematologic cancer	5.16e-05	0.00016	CcSEcCtD
Tapentadol—Urethral disorder—Doxorubicin—hematologic cancer	5.16e-05	0.00016	CcSEcCtD
Tapentadol—Decreased appetite—Dexamethasone—hematologic cancer	5.16e-05	0.00016	CcSEcCtD
Tapentadol—Decreased appetite—Betamethasone—hematologic cancer	5.16e-05	0.00016	CcSEcCtD
Tapentadol—Nausea—Irinotecan—hematologic cancer	5.15e-05	0.00016	CcSEcCtD
Tapentadol—Nausea—Mitoxantrone—hematologic cancer	5.15e-05	0.00016	CcSEcCtD
Tapentadol—Immune system disorder—Epirubicin—hematologic cancer	5.14e-05	0.00016	CcSEcCtD
Tapentadol—Infection—Prednisone—hematologic cancer	5.13e-05	0.00016	CcSEcCtD
Tapentadol—Mediastinal disorder—Epirubicin—hematologic cancer	5.12e-05	0.000159	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Betamethasone—hematologic cancer	5.12e-05	0.000159	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Dexamethasone—hematologic cancer	5.12e-05	0.000159	CcSEcCtD
Tapentadol—Fatigue—Dexamethasone—hematologic cancer	5.11e-05	0.000159	CcSEcCtD
Tapentadol—Fatigue—Betamethasone—hematologic cancer	5.11e-05	0.000159	CcSEcCtD
Tapentadol—Chills—Epirubicin—hematologic cancer	5.1e-05	0.000159	CcSEcCtD
Tapentadol—Pruritus—Etoposide—hematologic cancer	5.1e-05	0.000159	CcSEcCtD
Tapentadol—Shock—Prednisone—hematologic cancer	5.08e-05	0.000158	CcSEcCtD
Tapentadol—Visual impairment—Doxorubicin—hematologic cancer	5.07e-05	0.000158	CcSEcCtD
Tapentadol—Nervous system disorder—Prednisone—hematologic cancer	5.07e-05	0.000158	CcSEcCtD
Tapentadol—Tachycardia—Prednisone—hematologic cancer	5.04e-05	0.000157	CcSEcCtD
Tapentadol—Skin disorder—Prednisone—hematologic cancer	5.02e-05	0.000156	CcSEcCtD
Tapentadol—Nausea—Gemcitabine—hematologic cancer	5.01e-05	0.000156	CcSEcCtD
Tapentadol—Vomiting—Cisplatin—hematologic cancer	5e-05	0.000156	CcSEcCtD
Tapentadol—Hyperhidrosis—Prednisone—hematologic cancer	4.99e-05	0.000155	CcSEcCtD
Tapentadol—Vision blurred—Methotrexate—hematologic cancer	4.98e-05	0.000155	CcSEcCtD
Tapentadol—Mental disorder—Epirubicin—hematologic cancer	4.98e-05	0.000155	CcSEcCtD
Tapentadol—Rash—Cisplatin—hematologic cancer	4.96e-05	0.000154	CcSEcCtD
Tapentadol—Dermatitis—Cisplatin—hematologic cancer	4.96e-05	0.000154	CcSEcCtD
Tapentadol—Malnutrition—Epirubicin—hematologic cancer	4.95e-05	0.000154	CcSEcCtD
Tapentadol—Diarrhoea—Etoposide—hematologic cancer	4.93e-05	0.000153	CcSEcCtD
Tapentadol—Eye disorder—Doxorubicin—hematologic cancer	4.92e-05	0.000153	CcSEcCtD
Tapentadol—Feeling abnormal—Betamethasone—hematologic cancer	4.89e-05	0.000152	CcSEcCtD
Tapentadol—Feeling abnormal—Dexamethasone—hematologic cancer	4.89e-05	0.000152	CcSEcCtD
Tapentadol—Cardiac disorder—Doxorubicin—hematologic cancer	4.88e-05	0.000152	CcSEcCtD
Tapentadol—Tension—Epirubicin—hematologic cancer	4.86e-05	0.000151	CcSEcCtD
Tapentadol—Hypersensitivity—Triamcinolone—hematologic cancer	4.82e-05	0.00015	CcSEcCtD
Tapentadol—Nervousness—Epirubicin—hematologic cancer	4.81e-05	0.00015	CcSEcCtD
Tapentadol—Angiopathy—Doxorubicin—hematologic cancer	4.77e-05	0.000148	CcSEcCtD
Tapentadol—Dizziness—Etoposide—hematologic cancer	4.77e-05	0.000148	CcSEcCtD
Tapentadol—Immune system disorder—Doxorubicin—hematologic cancer	4.75e-05	0.000148	CcSEcCtD
Tapentadol—Vertigo—Methotrexate—hematologic cancer	4.75e-05	0.000148	CcSEcCtD
Tapentadol—Mediastinal disorder—Doxorubicin—hematologic cancer	4.74e-05	0.000147	CcSEcCtD
Tapentadol—Chills—Doxorubicin—hematologic cancer	4.72e-05	0.000147	CcSEcCtD
Tapentadol—Urticaria—Dexamethasone—hematologic cancer	4.71e-05	0.000147	CcSEcCtD
Tapentadol—Urticaria—Betamethasone—hematologic cancer	4.71e-05	0.000147	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Prednisone—hematologic cancer	4.71e-05	0.000146	CcSEcCtD
Tapentadol—Dizziness—Prednisolone—hematologic cancer	4.7e-05	0.000146	CcSEcCtD
Tapentadol—Asthenia—Triamcinolone—hematologic cancer	4.69e-05	0.000146	CcSEcCtD
Tapentadol—Nausea—Cisplatin—hematologic cancer	4.67e-05	0.000145	CcSEcCtD
Tapentadol—Insomnia—Prednisone—hematologic cancer	4.67e-05	0.000145	CcSEcCtD
Tapentadol—Vision blurred—Epirubicin—hematologic cancer	4.66e-05	0.000145	CcSEcCtD
Tapentadol—Paraesthesia—Prednisone—hematologic cancer	4.64e-05	0.000144	CcSEcCtD
Tapentadol—Pruritus—Triamcinolone—hematologic cancer	4.62e-05	0.000144	CcSEcCtD
Tapentadol—Cough—Methotrexate—hematologic cancer	4.62e-05	0.000144	CcSEcCtD
Tapentadol—Mental disorder—Doxorubicin—hematologic cancer	4.61e-05	0.000143	CcSEcCtD
Tapentadol—Convulsion—Methotrexate—hematologic cancer	4.58e-05	0.000143	CcSEcCtD
Tapentadol—Vomiting—Etoposide—hematologic cancer	4.58e-05	0.000143	CcSEcCtD
Tapentadol—Malnutrition—Doxorubicin—hematologic cancer	4.58e-05	0.000142	CcSEcCtD
Tapentadol—Agitation—Epirubicin—hematologic cancer	4.55e-05	0.000141	CcSEcCtD
Tapentadol—Dyspepsia—Prednisone—hematologic cancer	4.55e-05	0.000141	CcSEcCtD
Tapentadol—Rash—Etoposide—hematologic cancer	4.54e-05	0.000141	CcSEcCtD
Tapentadol—Dermatitis—Etoposide—hematologic cancer	4.54e-05	0.000141	CcSEcCtD
Tapentadol—Headache—Etoposide—hematologic cancer	4.51e-05	0.00014	CcSEcCtD
Tapentadol—Arthralgia—Methotrexate—hematologic cancer	4.5e-05	0.00014	CcSEcCtD
Tapentadol—Tension—Doxorubicin—hematologic cancer	4.49e-05	0.00014	CcSEcCtD
Tapentadol—Decreased appetite—Prednisone—hematologic cancer	4.49e-05	0.00014	CcSEcCtD
Tapentadol—Rash—Prednisolone—hematologic cancer	4.48e-05	0.000139	CcSEcCtD
Tapentadol—Dermatitis—Prednisolone—hematologic cancer	4.48e-05	0.000139	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	4.47e-05	0.000139	CcSEcCtD
Tapentadol—Fatigue—Prednisone—hematologic cancer	4.45e-05	0.000139	CcSEcCtD
Tapentadol—Headache—Prednisolone—hematologic cancer	4.45e-05	0.000139	CcSEcCtD
Tapentadol—Nervousness—Doxorubicin—hematologic cancer	4.45e-05	0.000138	CcSEcCtD
Tapentadol—Vertigo—Epirubicin—hematologic cancer	4.45e-05	0.000138	CcSEcCtD
Tapentadol—Syncope—Epirubicin—hematologic cancer	4.44e-05	0.000138	CcSEcCtD
Tapentadol—Constipation—Prednisone—hematologic cancer	4.42e-05	0.000137	CcSEcCtD
Tapentadol—Palpitations—Epirubicin—hematologic cancer	4.37e-05	0.000136	CcSEcCtD
Tapentadol—Confusional state—Methotrexate—hematologic cancer	4.35e-05	0.000135	CcSEcCtD
Tapentadol—Loss of consciousness—Epirubicin—hematologic cancer	4.35e-05	0.000135	CcSEcCtD
Tapentadol—Dizziness—Triamcinolone—hematologic cancer	4.32e-05	0.000134	CcSEcCtD
Tapentadol—Cough—Epirubicin—hematologic cancer	4.32e-05	0.000134	CcSEcCtD
Tapentadol—Anaphylactic shock—Methotrexate—hematologic cancer	4.32e-05	0.000134	CcSEcCtD
Tapentadol—Vision blurred—Doxorubicin—hematologic cancer	4.32e-05	0.000134	CcSEcCtD
Tapentadol—Convulsion—Epirubicin—hematologic cancer	4.29e-05	0.000133	CcSEcCtD
Tapentadol—Infection—Methotrexate—hematologic cancer	4.29e-05	0.000133	CcSEcCtD
Tapentadol—Nausea—Etoposide—hematologic cancer	4.28e-05	0.000133	CcSEcCtD
Tapentadol—Feeling abnormal—Prednisone—hematologic cancer	4.26e-05	0.000132	CcSEcCtD
Tapentadol—Asthenia—Dexamethasone—hematologic cancer	4.26e-05	0.000132	CcSEcCtD
Tapentadol—Asthenia—Betamethasone—hematologic cancer	4.26e-05	0.000132	CcSEcCtD
Tapentadol—Nervous system disorder—Methotrexate—hematologic cancer	4.23e-05	0.000132	CcSEcCtD
Tapentadol—Nausea—Prednisolone—hematologic cancer	4.22e-05	0.000131	CcSEcCtD
Tapentadol—Arthralgia—Epirubicin—hematologic cancer	4.21e-05	0.000131	CcSEcCtD
Tapentadol—Agitation—Doxorubicin—hematologic cancer	4.21e-05	0.000131	CcSEcCtD
Tapentadol—Anxiety—Epirubicin—hematologic cancer	4.2e-05	0.000131	CcSEcCtD
Tapentadol—Pruritus—Dexamethasone—hematologic cancer	4.2e-05	0.000131	CcSEcCtD
Tapentadol—Pruritus—Betamethasone—hematologic cancer	4.2e-05	0.000131	CcSEcCtD
Tapentadol—Skin disorder—Methotrexate—hematologic cancer	4.19e-05	0.00013	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	4.18e-05	0.00013	CcSEcCtD
Tapentadol—Hyperhidrosis—Methotrexate—hematologic cancer	4.17e-05	0.00013	CcSEcCtD
Tapentadol—Vomiting—Triamcinolone—hematologic cancer	4.16e-05	0.000129	CcSEcCtD
Tapentadol—Rash—Triamcinolone—hematologic cancer	4.12e-05	0.000128	CcSEcCtD
Tapentadol—Dry mouth—Epirubicin—hematologic cancer	4.12e-05	0.000128	CcSEcCtD
Tapentadol—Dermatitis—Triamcinolone—hematologic cancer	4.12e-05	0.000128	CcSEcCtD
Tapentadol—Vertigo—Doxorubicin—hematologic cancer	4.11e-05	0.000128	CcSEcCtD
Tapentadol—Syncope—Doxorubicin—hematologic cancer	4.11e-05	0.000128	CcSEcCtD
Tapentadol—Urticaria—Prednisone—hematologic cancer	4.1e-05	0.000128	CcSEcCtD
Tapentadol—Headache—Triamcinolone—hematologic cancer	4.09e-05	0.000127	CcSEcCtD
Tapentadol—Confusional state—Epirubicin—hematologic cancer	4.07e-05	0.000127	CcSEcCtD
Tapentadol—Diarrhoea—Betamethasone—hematologic cancer	4.06e-05	0.000126	CcSEcCtD
Tapentadol—Diarrhoea—Dexamethasone—hematologic cancer	4.06e-05	0.000126	CcSEcCtD
Tapentadol—Palpitations—Doxorubicin—hematologic cancer	4.05e-05	0.000126	CcSEcCtD
Tapentadol—Anaphylactic shock—Epirubicin—hematologic cancer	4.04e-05	0.000126	CcSEcCtD
Tapentadol—Oedema—Epirubicin—hematologic cancer	4.04e-05	0.000126	CcSEcCtD
Tapentadol—Hypotension—Methotrexate—hematologic cancer	4.03e-05	0.000125	CcSEcCtD
Tapentadol—Loss of consciousness—Doxorubicin—hematologic cancer	4.03e-05	0.000125	CcSEcCtD
Tapentadol—Infection—Epirubicin—hematologic cancer	4.01e-05	0.000125	CcSEcCtD
Tapentadol—Cough—Doxorubicin—hematologic cancer	4e-05	0.000124	CcSEcCtD
Tapentadol—Shock—Epirubicin—hematologic cancer	3.97e-05	0.000124	CcSEcCtD
Tapentadol—Convulsion—Doxorubicin—hematologic cancer	3.97e-05	0.000123	CcSEcCtD
Tapentadol—Nervous system disorder—Epirubicin—hematologic cancer	3.96e-05	0.000123	CcSEcCtD
Tapentadol—Tachycardia—Epirubicin—hematologic cancer	3.94e-05	0.000123	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Methotrexate—hematologic cancer	3.93e-05	0.000122	CcSEcCtD
Tapentadol—Skin disorder—Epirubicin—hematologic cancer	3.92e-05	0.000122	CcSEcCtD
Tapentadol—Dizziness—Betamethasone—hematologic cancer	3.92e-05	0.000122	CcSEcCtD
Tapentadol—Dizziness—Dexamethasone—hematologic cancer	3.92e-05	0.000122	CcSEcCtD
Tapentadol—Hyperhidrosis—Epirubicin—hematologic cancer	3.91e-05	0.000121	CcSEcCtD
Tapentadol—Insomnia—Methotrexate—hematologic cancer	3.9e-05	0.000121	CcSEcCtD
Tapentadol—Arthralgia—Doxorubicin—hematologic cancer	3.9e-05	0.000121	CcSEcCtD
Tapentadol—Anxiety—Doxorubicin—hematologic cancer	3.89e-05	0.000121	CcSEcCtD
Tapentadol—Nausea—Triamcinolone—hematologic cancer	3.88e-05	0.000121	CcSEcCtD
Tapentadol—Paraesthesia—Methotrexate—hematologic cancer	3.88e-05	0.000121	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	3.87e-05	0.00012	CcSEcCtD
Tapentadol—Dyspnoea—Methotrexate—hematologic cancer	3.85e-05	0.00012	CcSEcCtD
Tapentadol—Somnolence—Methotrexate—hematologic cancer	3.84e-05	0.000119	CcSEcCtD
Tapentadol—Dry mouth—Doxorubicin—hematologic cancer	3.81e-05	0.000119	CcSEcCtD
Tapentadol—Hypersensitivity—Prednisone—hematologic cancer	3.81e-05	0.000118	CcSEcCtD
Tapentadol—Dyspepsia—Methotrexate—hematologic cancer	3.8e-05	0.000118	CcSEcCtD
Tapentadol—Hypotension—Epirubicin—hematologic cancer	3.77e-05	0.000117	CcSEcCtD
Tapentadol—Vomiting—Betamethasone—hematologic cancer	3.77e-05	0.000117	CcSEcCtD
Tapentadol—Vomiting—Dexamethasone—hematologic cancer	3.77e-05	0.000117	CcSEcCtD
Tapentadol—Confusional state—Doxorubicin—hematologic cancer	3.77e-05	0.000117	CcSEcCtD
Tapentadol—Decreased appetite—Methotrexate—hematologic cancer	3.75e-05	0.000117	CcSEcCtD
Tapentadol—Rash—Betamethasone—hematologic cancer	3.74e-05	0.000116	CcSEcCtD
Tapentadol—Rash—Dexamethasone—hematologic cancer	3.74e-05	0.000116	CcSEcCtD
Tapentadol—Oedema—Doxorubicin—hematologic cancer	3.74e-05	0.000116	CcSEcCtD
Tapentadol—Anaphylactic shock—Doxorubicin—hematologic cancer	3.74e-05	0.000116	CcSEcCtD
Tapentadol—Dermatitis—Dexamethasone—hematologic cancer	3.74e-05	0.000116	CcSEcCtD
Tapentadol—Dermatitis—Betamethasone—hematologic cancer	3.74e-05	0.000116	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Methotrexate—hematologic cancer	3.73e-05	0.000116	CcSEcCtD
Tapentadol—Fatigue—Methotrexate—hematologic cancer	3.72e-05	0.000116	CcSEcCtD
Tapentadol—Headache—Dexamethasone—hematologic cancer	3.72e-05	0.000116	CcSEcCtD
Tapentadol—Headache—Betamethasone—hematologic cancer	3.72e-05	0.000116	CcSEcCtD
Tapentadol—Infection—Doxorubicin—hematologic cancer	3.71e-05	0.000116	CcSEcCtD
Tapentadol—Asthenia—Prednisone—hematologic cancer	3.71e-05	0.000115	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Epirubicin—hematologic cancer	3.68e-05	0.000114	CcSEcCtD
Tapentadol—Shock—Doxorubicin—hematologic cancer	3.68e-05	0.000114	CcSEcCtD
Tapentadol—Nervous system disorder—Doxorubicin—hematologic cancer	3.67e-05	0.000114	CcSEcCtD
Tapentadol—Pruritus—Prednisone—hematologic cancer	3.65e-05	0.000114	CcSEcCtD
Tapentadol—Insomnia—Epirubicin—hematologic cancer	3.65e-05	0.000114	CcSEcCtD
Tapentadol—Tachycardia—Doxorubicin—hematologic cancer	3.65e-05	0.000113	CcSEcCtD
Tapentadol—Skin disorder—Doxorubicin—hematologic cancer	3.63e-05	0.000113	CcSEcCtD
Tapentadol—Paraesthesia—Epirubicin—hematologic cancer	3.63e-05	0.000113	CcSEcCtD
Tapentadol—Hyperhidrosis—Doxorubicin—hematologic cancer	3.61e-05	0.000112	CcSEcCtD
Tapentadol—Dyspnoea—Epirubicin—hematologic cancer	3.6e-05	0.000112	CcSEcCtD
Tapentadol—Somnolence—Epirubicin—hematologic cancer	3.59e-05	0.000112	CcSEcCtD
Tapentadol—Feeling abnormal—Methotrexate—hematologic cancer	3.56e-05	0.000111	CcSEcCtD
Tapentadol—Dyspepsia—Epirubicin—hematologic cancer	3.56e-05	0.000111	CcSEcCtD
Tapentadol—Diarrhoea—Prednisone—hematologic cancer	3.53e-05	0.00011	CcSEcCtD
Tapentadol—Nausea—Betamethasone—hematologic cancer	3.52e-05	0.00011	CcSEcCtD
Tapentadol—Nausea—Dexamethasone—hematologic cancer	3.52e-05	0.00011	CcSEcCtD
Tapentadol—Decreased appetite—Epirubicin—hematologic cancer	3.51e-05	0.000109	CcSEcCtD
Tapentadol—Hypotension—Doxorubicin—hematologic cancer	3.49e-05	0.000109	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Epirubicin—hematologic cancer	3.49e-05	0.000108	CcSEcCtD
Tapentadol—Fatigue—Epirubicin—hematologic cancer	3.48e-05	0.000108	CcSEcCtD
Tapentadol—Constipation—Epirubicin—hematologic cancer	3.45e-05	0.000107	CcSEcCtD
Tapentadol—Urticaria—Methotrexate—hematologic cancer	3.43e-05	0.000107	CcSEcCtD
Tapentadol—Dizziness—Prednisone—hematologic cancer	3.42e-05	0.000106	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	3.41e-05	0.000106	CcSEcCtD
Tapentadol—Insomnia—Doxorubicin—hematologic cancer	3.38e-05	0.000105	CcSEcCtD
Tapentadol—Paraesthesia—Doxorubicin—hematologic cancer	3.36e-05	0.000104	CcSEcCtD
Tapentadol—Dyspnoea—Doxorubicin—hematologic cancer	3.33e-05	0.000104	CcSEcCtD
Tapentadol—Feeling abnormal—Epirubicin—hematologic cancer	3.33e-05	0.000104	CcSEcCtD
Tapentadol—Somnolence—Doxorubicin—hematologic cancer	3.32e-05	0.000103	CcSEcCtD
Tapentadol—Dyspepsia—Doxorubicin—hematologic cancer	3.29e-05	0.000102	CcSEcCtD
Tapentadol—Vomiting—Prednisone—hematologic cancer	3.28e-05	0.000102	CcSEcCtD
Tapentadol—Rash—Prednisone—hematologic cancer	3.26e-05	0.000101	CcSEcCtD
Tapentadol—Dermatitis—Prednisone—hematologic cancer	3.25e-05	0.000101	CcSEcCtD
Tapentadol—Decreased appetite—Doxorubicin—hematologic cancer	3.25e-05	0.000101	CcSEcCtD
Tapentadol—Headache—Prednisone—hematologic cancer	3.24e-05	0.000101	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Doxorubicin—hematologic cancer	3.23e-05	0.0001	CcSEcCtD
Tapentadol—Fatigue—Doxorubicin—hematologic cancer	3.22e-05	0.0001	CcSEcCtD
Tapentadol—Urticaria—Epirubicin—hematologic cancer	3.21e-05	9.98e-05	CcSEcCtD
Tapentadol—Constipation—Doxorubicin—hematologic cancer	3.2e-05	9.94e-05	CcSEcCtD
Tapentadol—Hypersensitivity—Methotrexate—hematologic cancer	3.18e-05	9.89e-05	CcSEcCtD
Tapentadol—Asthenia—Methotrexate—hematologic cancer	3.1e-05	9.63e-05	CcSEcCtD
Tapentadol—Feeling abnormal—Doxorubicin—hematologic cancer	3.08e-05	9.58e-05	CcSEcCtD
Tapentadol—Nausea—Prednisone—hematologic cancer	3.07e-05	9.54e-05	CcSEcCtD
Tapentadol—Pruritus—Methotrexate—hematologic cancer	3.05e-05	9.5e-05	CcSEcCtD
Tapentadol—Hypersensitivity—Epirubicin—hematologic cancer	2.98e-05	9.26e-05	CcSEcCtD
Tapentadol—Urticaria—Doxorubicin—hematologic cancer	2.97e-05	9.24e-05	CcSEcCtD
Tapentadol—Diarrhoea—Methotrexate—hematologic cancer	2.95e-05	9.19e-05	CcSEcCtD
Tapentadol—Asthenia—Epirubicin—hematologic cancer	2.9e-05	9.02e-05	CcSEcCtD
Tapentadol—Pruritus—Epirubicin—hematologic cancer	2.86e-05	8.89e-05	CcSEcCtD
Tapentadol—Dizziness—Methotrexate—hematologic cancer	2.85e-05	8.88e-05	CcSEcCtD
Tapentadol—Diarrhoea—Epirubicin—hematologic cancer	2.76e-05	8.6e-05	CcSEcCtD
Tapentadol—Hypersensitivity—Doxorubicin—hematologic cancer	2.75e-05	8.57e-05	CcSEcCtD
Tapentadol—Vomiting—Methotrexate—hematologic cancer	2.74e-05	8.54e-05	CcSEcCtD
Tapentadol—Rash—Methotrexate—hematologic cancer	2.72e-05	8.47e-05	CcSEcCtD
Tapentadol—Dermatitis—Methotrexate—hematologic cancer	2.72e-05	8.46e-05	CcSEcCtD
Tapentadol—Headache—Methotrexate—hematologic cancer	2.7e-05	8.41e-05	CcSEcCtD
Tapentadol—Asthenia—Doxorubicin—hematologic cancer	2.68e-05	8.34e-05	CcSEcCtD
Tapentadol—Dizziness—Epirubicin—hematologic cancer	2.67e-05	8.31e-05	CcSEcCtD
Tapentadol—Pruritus—Doxorubicin—hematologic cancer	2.64e-05	8.23e-05	CcSEcCtD
Tapentadol—Vomiting—Epirubicin—hematologic cancer	2.57e-05	7.99e-05	CcSEcCtD
Tapentadol—Nausea—Methotrexate—hematologic cancer	2.56e-05	7.98e-05	CcSEcCtD
Tapentadol—Diarrhoea—Doxorubicin—hematologic cancer	2.56e-05	7.95e-05	CcSEcCtD
Tapentadol—Rash—Epirubicin—hematologic cancer	2.55e-05	7.92e-05	CcSEcCtD
Tapentadol—Dermatitis—Epirubicin—hematologic cancer	2.54e-05	7.92e-05	CcSEcCtD
Tapentadol—Headache—Epirubicin—hematologic cancer	2.53e-05	7.87e-05	CcSEcCtD
Tapentadol—Dizziness—Doxorubicin—hematologic cancer	2.47e-05	7.69e-05	CcSEcCtD
Tapentadol—Nausea—Epirubicin—hematologic cancer	2.4e-05	7.46e-05	CcSEcCtD
Tapentadol—Vomiting—Doxorubicin—hematologic cancer	2.38e-05	7.39e-05	CcSEcCtD
Tapentadol—Rash—Doxorubicin—hematologic cancer	2.36e-05	7.33e-05	CcSEcCtD
Tapentadol—Dermatitis—Doxorubicin—hematologic cancer	2.35e-05	7.32e-05	CcSEcCtD
Tapentadol—Headache—Doxorubicin—hematologic cancer	2.34e-05	7.28e-05	CcSEcCtD
Tapentadol—Nausea—Doxorubicin—hematologic cancer	2.22e-05	6.91e-05	CcSEcCtD
Tapentadol—CYP2D6—Metabolism—ADCY7—hematologic cancer	8.01e-06	7.16e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—NCOA3—hematologic cancer	8.01e-06	7.16e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IL2RA—hematologic cancer	7.96e-06	7.12e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—NUP214—hematologic cancer	7.95e-06	7.11e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ADCY7—hematologic cancer	7.94e-06	7.1e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—NCOA3—hematologic cancer	7.94e-06	7.1e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	7.94e-06	7.1e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MAP2K1—hematologic cancer	7.92e-06	7.08e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—IL2—hematologic cancer	7.9e-06	7.06e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—NUP214—hematologic cancer	7.89e-06	7.05e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—SDC1—hematologic cancer	7.88e-06	7.04e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TERT—hematologic cancer	7.87e-06	7.04e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PIK3CD—hematologic cancer	7.87e-06	7.03e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CD80—hematologic cancer	7.86e-06	7.03e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PIK3CG—hematologic cancer	7.85e-06	7.02e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—KIT—hematologic cancer	7.85e-06	7.02e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—NRAS—hematologic cancer	7.85e-06	7.02e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	7.8e-06	6.98e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—MTR—hematologic cancer	7.79e-06	6.97e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ABCG2—hematologic cancer	7.79e-06	6.97e-05	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—PIK3CA—hematologic cancer	7.79e-06	6.97e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—MTR—hematologic cancer	7.73e-06	6.91e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ABCG2—hematologic cancer	7.73e-06	6.91e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PTPN11—hematologic cancer	7.71e-06	6.89e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—KRAS—hematologic cancer	7.7e-06	6.89e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PDGFB—hematologic cancer	7.68e-06	6.87e-05	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PIK3CB—hematologic cancer	7.65e-06	6.84e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ENO2—hematologic cancer	7.64e-06	6.83e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ENO2—hematologic cancer	7.58e-06	6.78e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—FGF2—hematologic cancer	7.53e-06	6.74e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	7.52e-06	6.73e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—CREBBP—hematologic cancer	7.52e-06	6.72e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—MAPK3—hematologic cancer	7.51e-06	6.72e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TSC2—hematologic cancer	7.51e-06	6.71e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CREB1—hematologic cancer	7.47e-06	6.68e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PIK3R1—hematologic cancer	7.43e-06	6.64e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	7.43e-06	6.64e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GSTT1—hematologic cancer	7.41e-06	6.63e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—BRAF—hematologic cancer	7.37e-06	6.6e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GSTT1—hematologic cancer	7.35e-06	6.57e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CCL2—hematologic cancer	7.31e-06	6.54e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—IL6R—hematologic cancer	7.29e-06	6.52e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CREBBP—hematologic cancer	7.27e-06	6.51e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—SDC1—hematologic cancer	7.24e-06	6.48e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	7.24e-06	6.47e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—FGFR3—hematologic cancer	7.22e-06	6.46e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—JAK2—hematologic cancer	7.22e-06	6.46e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—SDC1—hematologic cancer	7.18e-06	6.42e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MAPK14—hematologic cancer	7.15e-06	6.4e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PIK3CD—hematologic cancer	7.13e-06	6.38e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	7.1e-06	6.35e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—PIK3CA—hematologic cancer	7.08e-06	6.33e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MDM2—hematologic cancer	7.05e-06	6.3e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—ALB—hematologic cancer	7.04e-06	6.29e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—ESR1—hematologic cancer	7.01e-06	6.27e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MAP2K1—hematologic cancer	6.94e-06	6.21e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—FN1—hematologic cancer	6.93e-06	6.2e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PIK3CD—hematologic cancer	6.9e-06	6.17e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	6.86e-06	6.14e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PIK3CB—hematologic cancer	6.86e-06	6.13e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MTOR—hematologic cancer	6.86e-06	6.13e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—BAD—hematologic cancer	6.85e-06	6.12e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—NFKBIA—hematologic cancer	6.85e-06	6.12e-05	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—PIK3CA—hematologic cancer	6.83e-06	6.11e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—NOTCH1—hematologic cancer	6.78e-06	6.06e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	6.77e-06	6.06e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—KRAS—hematologic cancer	6.75e-06	6.04e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PIK3R1—hematologic cancer	6.73e-06	6.02e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CD44—hematologic cancer	6.7e-06	5.99e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—NQO1—hematologic cancer	6.7e-06	5.99e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CD80—hematologic cancer	6.64e-06	5.94e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PIK3CG—hematologic cancer	6.63e-06	5.93e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—KIT—hematologic cancer	6.63e-06	5.93e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—NRAS—hematologic cancer	6.63e-06	5.93e-05	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PTEN—hematologic cancer	6.61e-06	5.91e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—FGF2—hematologic cancer	6.6e-06	5.91e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	6.56e-06	5.86e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—HRAS—hematologic cancer	6.55e-06	5.85e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PTPN11—hematologic cancer	6.51e-06	5.83e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PIK3R1—hematologic cancer	6.51e-06	5.82e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	6.48e-06	5.79e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CDKN1B—hematologic cancer	6.43e-06	5.75e-05	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—AKT1—hematologic cancer	6.36e-06	5.69e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—MAPK3—hematologic cancer	6.35e-06	5.68e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CYCS—hematologic cancer	6.34e-06	5.67e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—JAK2—hematologic cancer	6.33e-06	5.66e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CREB1—hematologic cancer	6.31e-06	5.64e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CASP3—hematologic cancer	6.31e-06	5.64e-05	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—EP300—hematologic cancer	6.3e-06	5.64e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—HSP90AA1—hematologic cancer	6.3e-06	5.63e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—IL2—hematologic cancer	6.3e-06	5.63e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—IL6—hematologic cancer	6.27e-06	5.6e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—BRAF—hematologic cancer	6.23e-06	5.57e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PIK3CB—hematologic cancer	6.21e-06	5.56e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—PIK3CA—hematologic cancer	6.2e-06	5.55e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MDM2—hematologic cancer	6.18e-06	5.53e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CCL2—hematologic cancer	6.18e-06	5.52e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CD44—hematologic cancer	6.16e-06	5.51e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—NQO1—hematologic cancer	6.16e-06	5.51e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IL6R—hematologic cancer	6.16e-06	5.51e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CREBBP—hematologic cancer	6.15e-06	5.5e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CCND1—hematologic cancer	6.14e-06	5.49e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—JUN—hematologic cancer	6.13e-06	5.48e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—NQO1—hematologic cancer	6.11e-06	5.46e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CD44—hematologic cancer	6.11e-06	5.46e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MTOR—hematologic cancer	6.01e-06	5.38e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PIK3CB—hematologic cancer	6.01e-06	5.38e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	5.98e-06	5.35e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CDKN1A—hematologic cancer	5.94e-06	5.31e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PTEN—hematologic cancer	5.92e-06	5.3e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MAP2K1—hematologic cancer	5.87e-06	5.25e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PIK3CD—hematologic cancer	5.83e-06	5.21e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CYCS—hematologic cancer	5.83e-06	5.21e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MAPK8—hematologic cancer	5.8e-06	5.18e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—HSP90AA1—hematologic cancer	5.79e-06	5.18e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—AKT1—hematologic cancer	5.78e-06	5.17e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CYCS—hematologic cancer	5.78e-06	5.17e-05	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—PIK3CA—hematologic cancer	5.77e-06	5.16e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—HSP90AA1—hematologic cancer	5.74e-06	5.13e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—HRAS—hematologic cancer	5.74e-06	5.13e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—KRAS—hematologic cancer	5.71e-06	5.1e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	5.67e-06	5.07e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—EP300—hematologic cancer	5.65e-06	5.05e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CDKN1B—hematologic cancer	5.64e-06	5.05e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GSTP1—hematologic cancer	5.59e-06	5e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—FGF2—hematologic cancer	5.58e-06	4.99e-05	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—AKT1—hematologic cancer	5.58e-06	4.99e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CASP3—hematologic cancer	5.53e-06	4.95e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—IL2—hematologic cancer	5.52e-06	4.94e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PIK3R1—hematologic cancer	5.5e-06	4.92e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—SRC—hematologic cancer	5.49e-06	4.91e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—IL6—hematologic cancer	5.49e-06	4.91e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	5.4e-06	4.83e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CCND1—hematologic cancer	5.38e-06	4.81e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—JUN—hematologic cancer	5.37e-06	4.8e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PTEN—hematologic cancer	5.37e-06	4.8e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—VEGFA—hematologic cancer	5.35e-06	4.79e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—JAK2—hematologic cancer	5.35e-06	4.78e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—STAT3—hematologic cancer	5.3e-06	4.74e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ABCB1—hematologic cancer	5.29e-06	4.73e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—NRAS—hematologic cancer	5.29e-06	4.73e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—PIK3CA—hematologic cancer	5.24e-06	4.69e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MDM2—hematologic cancer	5.22e-06	4.67e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CDKN1A—hematologic cancer	5.21e-06	4.66e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PTEN—hematologic cancer	5.19e-06	4.65e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	5.17e-06	4.62e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GSTP1—hematologic cancer	5.14e-06	4.59e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—NCOR1—hematologic cancer	5.13e-06	4.59e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GSTM1—hematologic cancer	5.13e-06	4.59e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—EP300—hematologic cancer	5.12e-06	4.58e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GSTP1—hematologic cancer	5.09e-06	4.56e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MAPK8—hematologic cancer	5.08e-06	4.54e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PIK3CB—hematologic cancer	5.08e-06	4.54e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MTOR—hematologic cancer	5.08e-06	4.54e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—AKT1—hematologic cancer	5.07e-06	4.53e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MAPK3—hematologic cancer	5.06e-06	4.53e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—EP300—hematologic cancer	4.95e-06	4.43e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	4.93e-06	4.41e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MYC—hematologic cancer	4.92e-06	4.4e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—TGFB1—hematologic cancer	4.91e-06	4.39e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ABCB1—hematologic cancer	4.86e-06	4.35e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—HRAS—hematologic cancer	4.85e-06	4.34e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ABCB1—hematologic cancer	4.82e-06	4.31e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—SRC—hematologic cancer	4.82e-06	4.31e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CDKN1B—hematologic cancer	4.77e-06	4.26e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GSTM1—hematologic cancer	4.72e-06	4.22e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—NCOR1—hematologic cancer	4.72e-06	4.22e-05	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—AKT1—hematologic cancer	4.72e-06	4.22e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—VEGFA—hematologic cancer	4.69e-06	4.2e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—NCOR1—hematologic cancer	4.68e-06	4.19e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GSTM1—hematologic cancer	4.68e-06	4.19e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CASP3—hematologic cancer	4.67e-06	4.18e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IL2—hematologic cancer	4.67e-06	4.17e-05	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PIK3CA—hematologic cancer	4.66e-06	4.17e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—STAT3—hematologic cancer	4.65e-06	4.16e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—IL6—hematologic cancer	4.64e-06	4.15e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—NRAS—hematologic cancer	4.63e-06	4.14e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—KRAS—hematologic cancer	4.55e-06	4.07e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CCND1—hematologic cancer	4.55e-06	4.07e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—JUN—hematologic cancer	4.54e-06	4.06e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—MTHFR—hematologic cancer	4.54e-06	4.06e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MAPK3—hematologic cancer	4.44e-06	3.97e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CDKN1A—hematologic cancer	4.4e-06	3.94e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PTEN—hematologic cancer	4.39e-06	3.93e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MYC—hematologic cancer	4.32e-06	3.86e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—TGFB1—hematologic cancer	4.31e-06	3.85e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MAPK8—hematologic cancer	4.3e-06	3.84e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—AKT1—hematologic cancer	4.28e-06	3.83e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—EP300—hematologic cancer	4.19e-06	3.74e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PIK3CA—hematologic cancer	4.18e-06	3.74e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—MTHFR—hematologic cancer	4.17e-06	3.73e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—MTHFR—hematologic cancer	4.14e-06	3.7e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—SRC—hematologic cancer	4.07e-06	3.64e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—TP53—hematologic cancer	4.04e-06	3.62e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	4e-06	3.58e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—KRAS—hematologic cancer	3.99e-06	3.57e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—VEGFA—hematologic cancer	3.97e-06	3.55e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—STAT3—hematologic cancer	3.93e-06	3.51e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—NRAS—hematologic cancer	3.92e-06	3.5e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—HRAS—hematologic cancer	3.87e-06	3.46e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PIK3CG—hematologic cancer	3.81e-06	3.41e-05	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—AKT1—hematologic cancer	3.81e-06	3.41e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PIK3CA—hematologic cancer	3.79e-06	3.39e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MAPK3—hematologic cancer	3.75e-06	3.35e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—IL6—hematologic cancer	3.7e-06	3.31e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PIK3CA—hematologic cancer	3.66e-06	3.28e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MYC—hematologic cancer	3.65e-06	3.26e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	3.65e-06	3.26e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TGFB1—hematologic cancer	3.64e-06	3.26e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—TP53—hematologic cancer	3.55e-06	3.17e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CREBBP—hematologic cancer	3.53e-06	3.16e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PIK3CG—hematologic cancer	3.51e-06	3.14e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PIK3CG—hematologic cancer	3.48e-06	3.11e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—AKT1—hematologic cancer	3.41e-06	3.05e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—HRAS—hematologic cancer	3.39e-06	3.03e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—KRAS—hematologic cancer	3.37e-06	3.02e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PIK3CD—hematologic cancer	3.35e-06	3e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ALB—hematologic cancer	3.31e-06	2.96e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CREBBP—hematologic cancer	3.25e-06	2.91e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—IL6—hematologic cancer	3.25e-06	2.9e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CREBBP—hematologic cancer	3.22e-06	2.88e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PIK3R1—hematologic cancer	3.16e-06	2.83e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PIK3CA—hematologic cancer	3.1e-06	2.77e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—AKT1—hematologic cancer	3.09e-06	2.77e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PIK3CD—hematologic cancer	3.08e-06	2.76e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PIK3CD—hematologic cancer	3.06e-06	2.73e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ALB—hematologic cancer	3.04e-06	2.72e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ALB—hematologic cancer	3.02e-06	2.7e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TP53—hematologic cancer	3e-06	2.68e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—AKT1—hematologic cancer	2.99e-06	2.68e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PIK3CB—hematologic cancer	2.92e-06	2.61e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PIK3R1—hematologic cancer	2.91e-06	2.6e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PIK3R1—hematologic cancer	2.89e-06	2.58e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—HRAS—hematologic cancer	2.87e-06	2.56e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IL6—hematologic cancer	2.74e-06	2.45e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PIK3CB—hematologic cancer	2.69e-06	2.4e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PIK3CB—hematologic cancer	2.66e-06	2.38e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—AKT1—hematologic cancer	2.53e-06	2.26e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PTEN—hematologic cancer	2.52e-06	2.26e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—EP300—hematologic cancer	2.41e-06	2.15e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PTEN—hematologic cancer	2.32e-06	2.08e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PTEN—hematologic cancer	2.3e-06	2.06e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—EP300—hematologic cancer	2.21e-06	1.98e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—EP300—hematologic cancer	2.19e-06	1.96e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PIK3CA—hematologic cancer	1.78e-06	1.59e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PIK3CA—hematologic cancer	1.64e-06	1.46e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PIK3CA—hematologic cancer	1.62e-06	1.45e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—AKT1—hematologic cancer	1.45e-06	1.3e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—AKT1—hematologic cancer	1.34e-06	1.2e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—AKT1—hematologic cancer	1.33e-06	1.19e-05	CbGpPWpGaD
